Study suggests NSAIDs improve survival for certain colorectal cancer patients

June 15, 2017

Among long-term colorectal cancer survivors, use of nonsteroidal anti-inflammatory drugs, or NSAIDs, is associated with about a 25 percent reduction in all-cause mortality, according to new research from Fred Hutchinson Cancer Research Center to be published June 15 online in the Journal of Clinical Oncology.

The study further suggests that NSAIDs such as aspirin, ibuprofen and naproxen have a particularly advantageous effect when taken after diagnosis by colorectal, or CRC, patients without mutation in the KRAS gene (KRAS wild-type tumors): The study shows that NSAID use by this group is associated with a survival benefit of 40 percent. CRC is the second-leading cause of cancer-related deaths in the United States, and about 70 percent of CRC patients in this study have tumors without mutations in the KRAS gene.

"Several other studies have shown an association between NSAIDs and preventing CRC, but this is the first to look so thoroughly at how timing of NSAID use relative to diagnosis and tumor type could make a big difference in survival," said Dr. Polly Newcomb, an epidemiologist in the Public Health Division at Fred Hutch and senior author of the study. "These results should spark conversations between patients and their doctors. NSAID use is an accepted practice to prevent cardiovascular disease, and their use as a tool against cancer merits similar consideration and study."

The observational study used data from 2,419 newly diagnosed patients in the Colon Cancer Family Registry, an international consortium that collects lifestyle, family history and medical information from CRC patients from the U.S., Canada and Australia. The researchers were able to divide patients into four groups: those who took the drugs before as well as after diagnosis, those who initiated use post-diagnosis, those who quit use post-diagnosis and those who did not use them at all. The researchers also employed tumor-marker testing by genotyping patient samples to pinpoint tumor mutations and tumor type.

The study was conducted at Fred Hutch and included three other sites: the Mayo Clinic in Rochester, Minnesota; Cancer Care Ontario in Toronto, Canada; and the University of Melbourne in Melbourne, Australia, and followed patients for a median of 10.8 years after diagnosis. In the group, 42 percent regularly took some form of NSAIDs, both aspirin and non-aspirin.

To get the most accurate results, Newcomb and the research team controlled for factors such as smoking status, family history, age and other characteristics and then conducted statistical analyses to determine potential association of NSAID use to both overall and disease-specific survival. The team found some differences in type of NSAID and outcome, which they attribute to different patterns of use, such as dose or duration, rather than due to the type of NSAID.

Some limitations of the study include that it relied upon patients to self-report their NSAID use and the generalizability of the study may apply only to long-term CRC survivors. The team recommends that future efforts include a more racially diverse population.

"We now have a better idea of how NSAID use may benefit a subset of patients diagnosed with colorectal cancer," said Xinwei Hua, the study's first author and an epidemiologist at Fred Hutch. "Next, we need to understand more precisely what the optimal timing, dose and duration of NSAID use should be among patients with KRAS wild-type tumors. We are just beginning to understand the biology underpinning NSAID use on the tumor's molecular pathways, and it's very exciting."

Explore further: Long-term anti-inflammatory drug use may increase cancer-related deaths for certain patients

Related Stories

Long-term anti-inflammatory drug use may increase cancer-related deaths for certain patients

December 19, 2016
Regular use of over-the-counter non-steroidal inflammatory drugs (NSAIDs) such as aspirin and ibuprofen is associated with an increased risk of dying in patients diagnosed with Type 1 endometrial cancers, according to a new ...

Tolerance develops in NSAID-induced urticaria/angioedema

March 4, 2017
(HealthDay)—Patients with nonsteroidal anti-inflammatory drug (NSAID)-induced urticaria/angioedema (NIUA) may develop tolerance to NSAIDs over time, according to a study published online Feb. 22 in Allergy.

Researchers determine the best strategy for preventing ulcers when taking NSAIDs

May 13, 2016
Non-steroidal anti-inflammatory drugs (NSAIDs)—including ibuprofen, diclofenac, naproxen and others—are commonly used pain medications that are generally safe but may increase the risk of developing stomach and intestinal ...

NSAID use associated with lower colorectal cancer mortality rates among postmenopausal women

October 24, 2011
Postmenopausal women who reported having used nonsteroidal anti-inflammatory drugs for at least 10 years at the time of enrollment in the Women's Health Initiative study had a lower risk for death from colorectal cancer compared ...

Study examines NSAID use, risk of anastomotic failure following surgery

January 21, 2015
Use of nonsteroidal anti-inflammatory drugs (NSAIDs) was associated with an increased risk of anastomotic leak at the surgical junction in patients undergoing nonelective colorectal procedures, according to a report published ...

'Harmless' painkillers associated with increased risk of cardiac arrest

March 15, 2017
Painkillers considered harmless by the general public are associated with increased risk of cardiac arrest, according to research published today in the March issue of European Heart Journal - Cardiovascular Pharmacotherapy.

Recommended for you

Study shows how nerves drive prostate cancer

October 19, 2017
In a study in today's issue of Science, researchers at Albert Einstein College of Medicine, part of Montefiore Medicine, report that certain nerves sustain prostate cancer growth by triggering a switch that causes tumor vessels ...

Gene circuit switches on inside cancer cells, triggers immune attack

October 19, 2017
Researchers at MIT have developed a synthetic gene circuit that triggers the body's immune system to attack cancers when it detects signs of the disease.

One to 10 mutations are needed to drive cancer, scientists find

October 19, 2017
For the first time, scientists have provided unbiased estimates of the number of mutations needed for cancers to develop, in a study of more than 7,500 tumours across 29 cancer types. Researchers from the Wellcome Trust Sanger ...

Suicide molecules kill any cancer cell

October 19, 2017
Small RNA molecules originally developed as a tool to study gene function trigger a mechanism hidden in every cell that forces the cell to commit suicide, reports a new Northwestern Medicine study, the first to identify molecules ...

Researchers target undruggable cancers

October 19, 2017
A new approach to targeting key cancer-linked proteins, thought to be 'undruggable," has been discovered through an alliance between industry and academia.

Fundamental research enhances understanding of major cancer gene

October 19, 2017
New research represents a promising step towards better understanding of a key cancer gene. A long-running collaboration between researchers at the Babraham Institute, Cambridge and the AstraZeneca IMED Biotech Unit reveals ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.